Akums Drugs & Pharmaceuticals Ltd
AKUMSAkums Drugs & Pharmaceuticals Ltd's price has outrun its earnings. +20.3% in a year against EPS −24.6% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +20.3% in a year while annual EPS moved −24.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (13 weeks in) while the P/E sits at the 80th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit −46.0% year on year, and 357% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Akums Drugs & Pharmaceuticals Ltd trades at ₹665, in a confirmed uptrend and 13 weeks into that stage. That is +24.6% against its own 200-day average. It sits at 87% of a 52-week range of ₹420 to ₹702. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks.
Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹665 it trades +24.6% versus its 200-day average and sits at 87% of its 52-week range (₹420–₹702).
Against the market, two honest reads. Cumulative: over the last 1.9 years the stock moved −17% while the NIFTY 500 moved +3% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 29 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 80th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Akums Drugs & Pharmaceuticals Ltd trades at 40.3× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 26.6×, measured across 1.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 40.3× is at the pricey end of its own range (80th percentile), against a long-run median of 26.6× measured over 1.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −24.6% against a +20.3% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.7% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Akums Drugs & Pharmaceuticals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.9% | +6.0% | +9.9% | +10.2% |
| Profit | −25.6% | +37.7% | +15.8% | +15.4% |
| EPS | −24.6% | +34.7% | −55.6% | −29.4% |
| Share price | +20.3% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
54.0/100 — rank 17 of 43 in Pharma - Formulators · 72% evidence confidence
Akums Drugs & Pharmaceuticals Ltd scores 54.0 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 17. Price leads the evidence: RS versus the benchmark is 33.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 14.1 + 12.7 + 9.5 + 17.7 = 54. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Akums Drugs & Pharmaceuticals Ltd reported ₹1,158 Cr of revenue in the Mar 26 quarter, +9.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 11 years it has compounded at 10.4% a year. The last full year, FY26, came in at ₹4,359 Cr. The last four reported quarters add to ₹4,360 Cr.
Akums Drugs & Pharmaceuticals Ltd reported ₹1,158 Cr of revenue in the Mar 26 quarter, +9.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 11 years it has compounded at 10.4% a year. The last full year, FY26, came in at ₹4,359 Cr. The last four reported quarters add to ₹4,360 Cr.
FY26 revenue came in at ₹4,359 Cr (+5.9% on the year), capping 11 years at 10.4% compound. The latest quarter (Mar 26) printed ₹1,158 Cr, +9.7% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +5.9% growth against the decade's 10.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.9% over the last 4 quarters against +2.2%/yr over the last 8 — accelerating; TTM profit −25.3% vs +1,033.6%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 13.0% this quarter (+4.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Akums Drugs & Pharmaceuticals Ltd's operating margin is 13.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged −2.0% to 12.0%.
Akums Drugs & Pharmaceuticals Ltd's operating margin is 13.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged −2.0% to 12.0%.
The latest quarter's operating margin is 13.0%, +4.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged −2.0%–12.0%, and FY26's 12.0% is the top of that band — a record year.
Why the margin moved: operating margin went +4.2 pp year on year while gross margin went +3.5 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit −46.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Akums Drugs & Pharmaceuticals Ltd earned ₹81.0 Cr of net profit in the Mar 26 quarter, −46.0% year on year. Full-year FY26 profit was ₹256 Cr. The 11-year compound rate is 17.6%. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹150 Cr. 2 of the last 12 reported quarters were loss-making.
Akums Drugs & Pharmaceuticals Ltd earned ₹81.0 Cr of net profit in the Mar 26 quarter, −46.0% year on year. Full-year FY26 profit was ₹256 Cr. The 11-year compound rate is 17.6%. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹150 Cr. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹81.0 Cr, −46.0% year on year. On the full year, FY26 printed ₹256 Cr (−25.6%), and the 11-year compound rate is 17.6%.
🚨 Why profit moved: revenue contributed +9.7% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −18.0% vs revenue +5.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 357% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 357% of Akums Drugs & Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,181 Cr of operating cash against ₹256 Cr of profit. After ₹228 Cr of capital spending, ₹953 Cr was left as free cash.
FY26: operating cash of ₹1,181 Cr against reported profit of ₹256 Cr, leaving free cash of ₹953 Cr after ₹228 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 357% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 357%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹867 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Akums Drugs & Pharmaceuticals Ltd's cash conversion cycle runs 89 days in FY26, down from 90 days in FY21. Capital spending ran ₹867 Cr over the last 3 years. At FY26 sales of ₹4,359 Cr each day of that cycle holds about ₹11.9 Cr, so roughly ₹1,063 Cr sits inside the business at any moment.
FY26: debtors at 67 days, inventory at 110 days — roughly 3.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 89 days, tighter than FY21's 90.
The full loop: cash goes out to suppliers and production on day 0; stock waits 110 days to sell; customers pay about 67 days after that; and suppliers themselves are paid at 87 days — netting out to the 89-day cycle.
In money terms: at FY26 sales of ₹4,359 Cr, each day of the cycle holds about ₹11.9 Cr — so the 89-day loop keeps roughly ₹1,063 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹867 Cr over the last 3 fiscal years against ₹434 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹177 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 15%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Akums Drugs & Pharmaceuticals Ltd earns a ROCE of 15% in FY26. That is up from a trough of −16% in FY22. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 5.9% net margin on 0.80× asset turns.
FY26 ROCE is 15%, recovered from a FY22 trough of −16% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 5.9% net margin × 0.80× asset turns × 1.64× balance-sheet leverage ≈ 7.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.7% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.05.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Akums Drugs & Pharmaceuticals Ltd carries ₹157 Cr of borrowings against ₹3,314 Cr of equity in FY26, a debt-to-equity of 0.05. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹130 Cr to ₹157 Cr. Capital spending ran ₹867 Cr across the last 3 of those years.
FY26: borrowings of ₹157 Cr against equity of ₹3,314 Cr — a debt-to-equity of 0.05. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹130 Cr to ₹157 Cr while capital spending ran ₹867 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.7% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 5.9 points over 7 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 5.9 points of Akums Drugs & Pharmaceuticals Ltd over 7 quarters, the biggest move on the register. That takes domestic institutions to 13.4% of the company. Foreign institutions moved −5.4 points over the same window, to 1.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +5.9 points over 7 quarters to 13.4%; Foreign institutions: −5.4 points over 7 quarters to 1.9%; Promoters: +0.0 points over 7 quarters to 75.3%.
Why the register moved: rotation — foreign institutions −5.4 points against domestic institutions +5.9 points over 7 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Akums Drugs & Pharmaceuticals Ltd: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
The safety line in one sentence: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Akums Drugs & Pharmaceuticals Ltd this page | 40.3× | ₹10,818 Cr | No read | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Akums Drugs & Pharmaceuticals Ltd's share price today?
Akums Drugs & Pharmaceuticals Ltd trades at ₹665, +20.3% over the past year. The company is valued at ₹10,818 Cr. The stock sits at 87% of its 52-week range of ₹420–₹702, +24.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 24 July 2026.
What were Akums Drugs & Pharmaceuticals Ltd's latest quarterly results?
Akums Drugs & Pharmaceuticals Ltd reported revenue of ₹1,158 Cr and net profit of ₹81.0 Cr for the Mar 26 quarter. Revenue rose 9.7% and profit fell 46.0% year on year. Earnings per share were ₹5.38. The operating margin was 13.0%, 4.0 pp higher than a year earlier. — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's revenue?
Akums Drugs & Pharmaceuticals Ltd reported revenue of ₹1,158 Cr in the Mar 26 quarter, +9.7% year on year. For the full FY26 fiscal year, revenue was ₹4,359 Cr (+5.9%). Over the last 11 years revenue compounded at 10.4% a year. — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's profit?
Akums Drugs & Pharmaceuticals Ltd earned ₹81.0 Cr of net profit in the Mar 26 quarter, −46.0% year on year. Full-year FY26 profit was ₹256 Cr. The operating margin ran 13.0% in the latest quarter. — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's market cap?
Akums Drugs & Pharmaceuticals Ltd's market capitalisation is ₹10,818 Cr at a share price of ₹665. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's P/E ratio?
Akums Drugs & Pharmaceuticals Ltd trades at a P/E of 40.3×, at the 80th percentile of its own 2-year range, against a long-run median of 26.6×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Akums Drugs & Pharmaceuticals Ltd pay a dividend?
Yes — Akums Drugs & Pharmaceuticals Ltd's dividend payout was 18% of profit in FY26, and it recorded a payout in 1 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd overvalued?
On its own history, Akums Drugs & Pharmaceuticals Ltd looks expensive against its own history: its P/E of 40.3× sits at the 80th percentile of its 2-year range (long-run median 26.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd growing?
Yes — Akums Drugs & Pharmaceuticals Ltd is growing: latest-quarter revenue +9.7% year on year, profit −46.0%, and the margin +4.0 pp at 13.0%. The 11-year compound rates are 10.4% (revenue) and 17.6% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Akums Drugs & Pharmaceuticals Ltd performing?
Akums Drugs & Pharmaceuticals Ltd is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 9.7% and profit fell 46.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 29 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +24.6% versus its 200-day average and at 87% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd beating the market?
On recent form, yes — Akums Drugs & Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 29 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.9 years the stock moved −17% against the NIFTY 500's +3% — behind the index over the full window. — as of 24 July 2026.
Will Akums Drugs & Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Akums Drugs & Pharmaceuticals Ltd. What it measures instead: the share price is ₹665, the price is in a confirmed uptrend 13 weeks in. Its P/E of 40.3× sits at the 80th percentile of its own 2-year range. — as of 24 July 2026.
Who owns Akums Drugs & Pharmaceuticals Ltd?
Promoters hold 75.3% of Akums Drugs & Pharmaceuticals Ltd, foreign institutions 1.9%, domestic institutions 13.4% and the public 6.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 5.9 points over 7 quarters. — as of 24 July 2026.
Does Akums Drugs & Pharmaceuticals Ltd have too much debt?
No — Akums Drugs & Pharmaceuticals Ltd's debt-to-equity is 0.05, and operating profit covers the interest bill 6×. FY26 borrowings were ₹157 Cr against equity of ₹3,314 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's capex?
Akums Drugs & Pharmaceuticals Ltd spent ₹867 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹228 Cr, with ₹177 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Akums Drugs & Pharmaceuticals Ltd's cash flow?
Akums Drugs & Pharmaceuticals Ltd generated ₹1,181 Cr of operating cash flow in FY26 and ₹953 Cr of free cash flow after ₹228 Cr of capital spending. Reported profit that year was ₹256 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 357% of Akums Drugs & Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,181 Cr against reported profit of ₹256 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Akums Drugs & Pharmaceuticals Ltd in its business cycle?
Akums Drugs & Pharmaceuticals Ltd's FY26 operating margin was 12.0%, against a 9-year band of −2.0%–12.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Akums Drugs & Pharmaceuticals Ltd story?
The sharpest disagreement: the price moved +20.3% in a year while annual EPS moved −24.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Akums Drugs & Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Akums Drugs & Pharmaceuticals Ltd's price has outrun its earnings. +20.3% in a year against EPS −24.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.